Arvinas Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arvinas wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Arvinas saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 1,800,000 shares, a decline of 70.3% from the December 31st total of 6,070,000 shares. Based on an average daily volume of 1,180,000 shares, the days-to-cover ratio is presently 1.5 days.
View Arvinas' Short Interest.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Arvinas.

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.11. The business earned $7.60 million during the quarter, compared to analysts' expectations of $5.68 million. Arvinas had a negative net margin of 403.77% and a negative trailing twelve-month return on equity of 46.99%.
View Arvinas' earnings history.

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARVN stock has increased by 72.8% and is now trading at $76.14.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued twelve-month price targets for Arvinas' shares. Their forecasts range from $45.00 to $129.00. On average, they expect Arvinas' share price to reach $105.91 in the next year. This suggests a possible upside of 39.1% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Some companies that are related to Arvinas include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Grifols (GRFS), Mirati Therapeutics (MRTX), Dr. Reddy's Laboratories (RDY), BridgeBio Pharma (BBIO), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), United Therapeutics (UTHR) and Schrödinger (SDGR).
View all of ARVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional investors include Canaan Partners IX LLC (7.41%), BlackRock Inc. (5.82%), Price T Rowe Associates Inc. MD (4.64%), Avidity Partners Management LP (3.69%), JPMorgan Chase & Co. (3.33%) and Northern Trust Corp (0.81%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, SG Americas Securities LLC, Morgan Stanley, Squarepoint Ops LLC, Engineers Gate Manager LP, Candriam Luxembourg S.C.A., First Trust Advisors LP, and Federated Hermes Inc.. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas or view top insider-selling stocks.

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BlackRock Inc., JPMorgan Chase & Co., Avidity Partners Management LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Caas Capital Management LP, and Renaissance Technologies LLC. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Ian Taylor, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or or view top insider-buying stocks.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $76.14.

Arvinas has a market capitalization of $3.69 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

Arvinas employs 133 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]